GLO1 inhibitors have been investigated for their effects on dicarbonyl stress in various pathologies, including atherosclerosis (36), diabetes and its vascular complications (37), osteoporosis (38), anxiety-linked behavior (39), and age-related decline in heart function (40). The gene discussed is GLO1; the disease is diabetes mellitus.